Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates
05 mai 2022 07h30 HE
|
Avalo Therapeutics
Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion deficiency type II (LAD II)Executed workforce...
Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference
08 mars 2022 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
02 mars 2022 07h30 HE
|
Avalo Therapeutics
Dr. Garry Neil and Chris Sullivan promoted to Chief Executive Officer and Chief Financial Officer, respectivelyAnnounced plans to initiate a Phase 2 randomized, double-blind, placebo-controlled trial...
Avalo Therapeutics Announces Leadership Transition
17 févr. 2022 07h30 HE
|
Avalo Therapeutics
Promotes Dr. Garry Neil to Chief Executive OfficerPromotes Chris Sullivan to Chief Financial Officer WAYNE, Pa. and ROCKVILLE, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc....
Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference
07 févr. 2022 16h01 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
10 janv. 2022 19h59 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo” or the “Company”), a leading clinical-stage precision medicine company that...
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
06 janv. 2022 07h30 HE
|
Avalo Therapeutics
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseasesEfficacy signal demonstrated in heavily...
Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022
16 déc. 2021 07h30 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Appoints Two New Independent Directors to Its Board
06 déc. 2021 07h30 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo to Present at Two Upcoming Conferences
11 nov. 2021 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...